Smokers run increased risk of developing anti-natalizumab antibodies

Multiple Sclerosis Journal

Volumn 20, Issue 8, 2014, Pages 1081-1085

  Hedstrom A K ^a   Alfredsson, L ^a   Lundkvist Ryner, M ^b   Fogdell Hahn, A ^b   Hillert, Jan ^b   Olsson, T ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

immunology; Multiple sclerosis; smoking; Tysabri

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB; NEUTRALIZING ANTIBODY; DRUG ANTIBODY; HLA ANTIGEN; HLA DRB1 ANTIGEN; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CASE CONTROL STUDY; CLINICAL IMMUNOLOGY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RISK; SMOKING; SMOKING HABIT; TREATMENT OUTCOME; ANTIBODY DETECTION; ANTIBODY RESPONSE; BIOLOGICAL THERAPY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; HUMAN CELL; IMMUNOGENICITY; IMMUNOREACTIVITY; LUNG; PASSIVE SMOKING; POPULATION BASED CASE CONTROL STUDY; SNUFF USER; BLOOD; HABIT; IMMUNOLOGY; MULTIVARIATE ANALYSIS; ODDS RATIO; REGISTER; RISK FACTOR; STATISTICAL MODEL; SWEDEN; TIME FACTOR;

ADULT; ANTIBODIES, NEUTRALIZING; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HABITS; HUMANS; IMMUNOLOGIC FACTORS; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS; MULTIVARIATE ANALYSIS; NATALIZUMAB; ODDS RATIO; REGISTRIES; RISK FACTORS; SMOKERS; SMOKING; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84904806843     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513515086     Document Type: Article

References (12)

1. Hutchingson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 ; 256: 405-415
2. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology. 2007 ; 69: 1391-1403 (Pubitemid 47511460)
3. Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler. 2013 ; 19: 593-600
4. Freemer MM, King TE, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. Ann Rheum Dis. 2006 ; 65: 581-584
5. Hedström AK, Ryner M, Fink K, et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon. Mult Scler. :
6. Hedström AK, Åkerstedt T, Hillert, et al. Shift work at young age is associated with increased risk for multiple sclerosis. Ann Neurol. 2011 ; 70: 733-741
7. Hedström AK, Bomfim I, Barcellos LF, et al. Interaction between adolescent obesity and HLA risk genes in the development of multiple sclerosis.. :
8. Lundkvist M, Engdahl E, Holmén C, et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler. 2013 ; 19: 757-764
9. Makrygiannakis D, Hermansson M, Ulfgren AK, et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann Rheum Dis. 2008 ; 67: 1488-1492
10. Doyle HA, Mamula MJ. Posttranslational protein modifications: New flavors in the menu of autoantigens. Curr Opin Rheumatol. 2002 ; 14: 244-249 (Pubitemid 34439088)
11. Cloos PA, Christgau S. Post-translational modifications of proteins: Implications for aging, antigen recognition, and autoimmunity. Biogerontology. 2004 ; 5: 139-158 (Pubitemid 39004541)
12. Wingerchuk DM. Smoking: Effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord. 2012 ; 5: 13-22